After 2022 Slowdown, WuXi Biologics Gets Growth Medicine From Big New Order
China’s leading provider of outsourced medical services said its profit and revenue rose 48.4% and 30% last year, respectively, marking a significant slowdown from the previous yearKey Takeaways:WuXi Biologics revenue…
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
‘Revenge travel’ slowdown puts damper on Trip.com’s banner year
9961.HK
- Atour relies on network expansion to counter economic slowdown
- TCMTech fuses old with the new by mixing AI and Chinese medicine
-
Ninja Turtles slowdown breaks Playmates two-year winning streak
0869.HK
-
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK 603259.SHG
